Incretin metabolic peptides: what the trials actually show

A STACKD synthesis of the GLP-1 / GIP / glucagon class most people mean by “metabolic peptides.”

Plain-language summary

Semaglutide, tirzepatide, and retatrutide all borrow from the same biology: the gut hormones your body releases after eating. Semaglutide copies one of them (GLP-1). Tirzepatide copies two (GLP-1 and GIP). Retatrutide adds a third lever (glucagon). Across large, well-run trials, hitting more of these receptors has generally produced larger average weight and blood-sugar changes, but every one of these studies was done under medical supervision, in defined patient groups, not in healthy lifters experimenting on their own.

What was studied

Randomized controlled trials measuring average body-weight change and glycemic markers (like HbA1c) over roughly 40-72 weeks, in adults with obesity and/or type 2 diabetes. Semaglutide and tirzepatide also have cardiovascular and head-to-head data; retatrutide is earlier, with Phase 2 results as the current high-water mark.

Key takeaways

Directionally, more receptor coverage has tracked with bigger average weight loss in trials: GLP-1 (semaglutide) → dual GIP/GLP-1 (tirzepatide) → triple agonist (retatrutide).
These are among the strongest evidence bases of any peptide discussed in fitness circles, the opposite end of the spectrum from research-only compounds.
Benefits were measured against placebo in supervised trials, so real-world results depend heavily on adherence, nutrition, and clinical oversight.
Gastrointestinal side effects (nausea, etc.) are common across the whole class.

Multi-study synthesis

Read as a class, the incretin trials tell a fairly consistent story: engaging more of the gut-hormone system tends to move the average metabolic needle further, and the effect sizes are unusually large and repeatable for this field. The honest caveat is that “larger average effect in a supervised obesity trial” is not the same claim as “better or safer for a healthy person chasing body recomposition.” The evidence is strong for what it measured, and silent on a lot of what fitness audiences actually want to know.

Limitations & what we don't know

Retatrutide is investigational and not broadly approved for consumer use as of last review; long-term safety data are still maturing.
Rapid weight loss can include lean mass, and rebound after stopping is documented, trials don't automatically translate to a lifter's goals.
Trial populations (obesity, type 2 diabetes) are not the same as healthy athletes, so extrapolation is a leap.
Approval status differs by molecule and region; these are prescription or investigational drugs, not DIY research chemicals.

Sources

Primary citations behind this summary. External links are provided for verification, read them yourself before drawing conclusions.

1.
Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)
2021 · human
Clinically meaningful weight loss vs placebo.
2.
Semaglutide and Cardiovascular Outcomes in Type 2 Diabetes (SUSTAIN-6)
2016 · human
Cardiovascular outcome findings for semaglutide.
3.
Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)
2022 · human
Substantial weight reduction vs placebo.
4.
Tirzepatide versus Semaglutide Once Weekly in Type 2 Diabetes (SURPASS-2)
2021 · human
Head-to-head outcomes favored tirzepatide.
5.
Triple-Hormone-Receptor Agonist Retatrutide for Obesity, A Phase 2 Trial
2023 · human
Dose-dependent weight loss over 48 weeks.
6.
Retatrutide for People with Type 2 Diabetes
2023 · human
Glycemic and weight outcomes in T2D.